Covid-19 roundup: Eu­rope is ‘weeks away’ from remde­sivir de­ci­sion; John Far­ley gets per­ma­nent gig as chief of FDA di­vi­sion steer­ing pan­dem­ic re­sponse

Gilead’s remde­sivir — the first drug shown to ben­e­fit Covid-19 pa­tients in a ran­dom­ized, con­trolled tri­al set­ting — is po­ten­tial­ly a hop, skip and a jump away from se­cur­ing Eu­ro­pean en­dorse­ment for Covid-19.

A rolling ap­pli­ca­tion was kicked off for the ther­a­py in late April, and on Mon­day, the EMA said it ex­pect­ed to pub­lish its opin­ion “with­in weeks.” Pre­vi­ous­ly, the reg­u­la­tor rec­om­mend­ed ex­pand­ing com­pas­sion­ate use of remde­sivir in se­vere Covid-19 pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.